Multiple Myeloma Therapy Targets, Resistance Pathways Identified With Single-Cell Sequencing

NEW YORK – After conducting a prospective, multicenter, single-arm clinical trial of multiple myeloma (MM) combined with a longitudinal single-cell RNA-sequencing (scRNA-seq) study of the disease's molecular underpinnings, researchers in Israel identified new molecular pathways of resistance, including hypoxia tolerance, protein folding, and mitochondria respiration.